EUVIMED · CrossrefJournal
Biologics in Therapy
ISSN 2195-5840 · Springer Science and Business Media LLC
Latest articles
Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab
Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands
Brentuximab Vedotin in CD30+ Lymphomas
Current and Novel Treatment Options for Metastatic Colorectal Cancer: Emphasis on Aflibercept
The Role of Biological and Small Molecule Therapy in the Management of Psoriatic Arthritis
Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden
Golimumab: A Novel Anti-Tumor Necrosis Factor
Weekly Teriparatide for Delayed Unions of Atypical Subtrochanteric Femur Fractures
One-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age
To the Editor; A Commentary on “Switching From Originator to Biosimilar Human Growth Hormone Using a Dialogue Teamwork: Single-Center Experience From Sweden”
Isoagglutinin Reduction in Human Immunoglobulin Products by Donor Screening
Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System
Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency
Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting
Erratum to: Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System
Publisher’s Note
EUVIMED